title: Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.
abstract: BACKGROUND
  To characterise recurrence patterns and survival following pathologic complete response (pCR) in patients who received preoperative therapy for localised gastric or gastrooesophageal junction (GEJ) adenocarcinoma.
  
  
  METHODS
  A retrospective review of a prospective database identified patients with pCR after preoperative chemotherapy for gastric or preoperative chemoradiation for GEJ (Siewert II/III) adenocarcinoma. Recurrence patterns, overall survival, recurrence-free survival, and disease-specific survival were analysed.
  
  
  RESULTS
  From 1985 to 2009, 714 patients received preoperative therapy for localised gastric/GEJ adenocarcinoma, and 609 (85%) underwent a subsequent R0 resection. There were 60 patients (8.4%) with a pCR. Median follow-up was 46 months. Recurrence at 5 years was significantly lower for pCR vs non-pCR patients (27% and 51%, respectively, P=0.01). The probability of recurrence for patients with pCR was similar to non-pCR patients with pathologic stage I or II disease. Although the overall pattern of local/regional (LR) vs distant recurrence was comparable (43% LR vs 57% distant) between pCR and non-pCR groups, there was a significantly higher incidence of central nervous system (CNS) first recurrences in pCR patients (36 vs 4%, P=0.01).
  
  
  CONCLUSIONS
  Patients with gastric or GEJ adenocarcinoma who achieve a pCR following preoperative therapy still have a significant risk of recurrence and cancer-specific death following resection. One third of the recurrences in the pCR group were symptomatic CNS recurrences. Increased awareness of the risk of CNS metastases and selective brain imaging in patients who achieve a pCR following preoperative therapy for gastric/GEJ adenocarcinoma is warranted.
authors: Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors: R C
authors: RC
authors: Fields
authors: V E
authors: VE
authors: Strong
authors: M
authors: M
authors: Gönen
authors: K A
authors: KA
authors: Goodman
authors: N P
authors: NP
authors: Rizk
authors: D P
authors: DP
authors: Kelsen
authors: D H
authors: DH
authors: Ilson
authors: L H
authors: LH
authors: Tang
authors: M F
authors: MF
authors: Brennan
authors: D G
authors: DG
authors: Coit
authors: M A
authors: MA
authors: Shah
references: Clin Cancer Res. 2008 Apr 1;14(7):2012-8
references: 18381939
references: JAMA. 2010 May 5;303(17):1753-4
references: 20442394
references: Dis Colon Rectum. 2004 Nov;47(11):1798-807
references: 15622571
references: JAMA. 2010 May 5;303(17):1723-8
references: 20442388
references: J Clin Oncol. 2009 Apr 20;27(12):1956-62
references: 19273696
references: Cancer. 2005 Oct 1;104(7):1349-55
references: 16130133
references: J Clin Oncol. 2005 Mar 1;23(7):1530-7
references: 15735128
references: J Clin Oncol. 2006 May 10;24(14):2137-50
references: 16682732
references: N Engl J Med. 2001 Sep 6;345(10):725-30
references: 11547741
references: Ann Oncol. 2006 Sep;17(9):1404-11
references: 16788003
references: J Clin Oncol. 2005 Jul 1;23(19):4256-8
references: 15781878
references: J Clin Oncol. 2009 Feb 20;27(6):851-6
references: 19139439
references: Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-77-S19-81
references: 9427272
references: Br J Cancer. 2004 Oct 4;91(7):1229-35
references: 15305188
references: J Clin Oncol. 2004 Jan 1;22(1):45-52
references: 14701767
references: Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1945-52
references: 19531677
references: J Clin Oncol. 1992 Apr;10(4):541-8
references: 1548519
references: J Clin Oncol. 2005 Jul 1;23(19):4330-7
references: 15781882
references: Lancet Oncol. 2007 Sep;8(9):797-805
references: 17693134
references: J Clin Oncol. 2010 Dec 10;28(35):5210-8
references: 21060024
references: Br J Cancer. 2007 Jun 18;96(12):1823-7
references: 17533399
references: Ann Thorac Surg. 2009 Feb;87(2):392-8; discussion 398-9
references: 19161745
references: Cancer. 2007 Apr 15;109(8):1668-75
references: 17342770
references: Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):158-9
references: 18985342
references: Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
references: 15383798
references: Lancet Oncol. 2010 Sep;11(9):835-44
references: 20692872
references: J Clin Oncol. 2006 Aug 1;24(22):3570-5
references: 16877723
references: Cancer. 2000 Feb 15;88(4):921-32
references: 10679663
references: Am J Gastroenterol. 2010 Feb;105(2):420-33
references: 19809407
references: J Clin Oncol. 2007 Oct 1;25(28):4414-22
references: 17785706
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7
references: 12167786
references: J Clin Oncol. 2011 Jan 20;29(3):272-8
references: 21135270
references: J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
references: 17374833
references: Ann Surg. 2009 Mar;249(3):392-6
references: 19247024
references: Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7
references: 20888705
references: J Natl Cancer Inst Monogr. 2001;(30):96-102
references: 11773300
references: N Engl J Med. 2006 Jul 6;355(1):11-20
references: 16822992
references: Breast Cancer Res Treat. 2010 Dec;124(3):723-32
references: 20878462
references: Ann Surg Oncol. 2007 Dec;14(12):3412-8
references: 17909917
references: Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):741-7
references: 18164837
references: Cancer. 2010 Sep 1;116(17):4168-77
references: 20564153
references: Biometrics. 1978 Dec;34(4):541-54
references: 373811